Myelodysplastic Syndromes (MDS)
Recent advances in cell therapy for AML/MDS.
Yokoyama H
A comprehensive review published in the International Journal of Hematology highlights that cellular immunotherapy, while transformative for B-cell leukemias, lymphomas, and multiple myeloma, has yet to achieve comparable breakthroughs in acute myeloid leukemia (AML) and myelodysplastic syndromes (M…
Source →Corrigendum to "Qinghuang powder ameliorates cellular senescence and energy metabolism abnormalities in bone marrow mesenchymal stem cells of myelodysplastic syndromes" [J. Ethnopharmacol. 373 (2026) 122323].
Jiang P, et al
This publication is a corrigendum (formal correction notice) to a previously published study examining how Qinghuang powder — a traditional Chinese herbal formulation — affects cellular senescence and energy metabolism abnormalities in bone marrow mesenchymal stem cells derived from patients with my…
Source →Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.
Tian L, et al
A study of 371 aplastic anemia (AA) patients receiving immunosuppressive therapy (IST) found that the rate of detectable somatic mutations nearly doubled — from 22% (53 of 237 patients) at baseline to 41% (97 of 237) after treatment — underscoring the substantial risk of clonal evolution in this bon…
Source →Clinical and molecular spectrum of VEXAS with multiple UBA1 variants: case study and literature review.
Das R, et al
Researchers report a novel case of VEXAS syndrome harboring 3 independent UBA1-mutated clones — variants p.M41V, p.M41L, and c.118-2A > T — detected by droplet digital PCR and next-generation sequencing, making this only the fourth reported case in the literature of VEXAS with multiple concurrent UB…
Source →Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.
Santini V, et al
The phase III IMerge trial demonstrated that imetelstat, a first-in-class telomerase inhibitor, provided clinically meaningful transfusion independence and favorable long-term overall survival outcomes compared with placebo in patients with lower-risk myelodysplastic syndromes (MDS) who had relapsed…
Source →Integrative bioinformatic analysis delineates a mitochondrial-hematopoietic gene signature for diagnosis and immune characterization in myelodysplastic syndromes.
Liu X, et al
Researchers developed a 17-gene mitochondrial-hematopoietic diagnostic signature that achieved high accuracy for detecting myelodysplastic syndromes (MDS), with an AUC of 0.963, using machine learning methods applied to three integrated microarray datasets (GSE145733, GSE19429, GSE81173). FGF2 was i…
Source →Concomitant oral and genital mucosal involvement in classical Sweet syndrome.
Ragonesi S, et al
A case report published in Dermatology Reports describes a rare presentation of classical Sweet syndrome (SS) featuring simultaneous oral and genital mucosal involvement, highlighting an underrecognized clinical manifestation of this neutrophilic dermatosis. Sweet syndrome, classified into classical…
Source →Infection risk in myelodysplastic syndromes is dynamic and immune driven.
Pradhan A, et al
A retrospective study of 708 patients with myelodysplastic syndromes (MDS) found that infection is a dynamic, immune-driven complication with profound prognostic consequences: 78.8% of patients required hospitalization, of which 69.9% were infection-related, and infection-related hospitalization was…
Source →RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.
Espinosa JA, et al
A review published in Trends in Cancer identifies RBM15 as a pivotal molecular regulator that connects RNA metabolism, N6-methyladenosine (m6A) epitranscriptomic modification, and blood cell lineage decisions to leukemia development, most critically through its involvement in the RBM15::MKL1 gene fu…
Source →VEXAS Syndrome: Report of One Case
Liu H, et al
Clinicians in China have confirmed a diagnosis of VEXAS syndrome in an elderly male patient through identification of a UBA1 gene mutation (c.121A>C, p.Met41Val), underscoring the importance of integrating multiple clinical clues to reach this rare and complex diagnosis. The patient presented with f…
Source →Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis.
Williamson J, et al
A retrospective, literature-based micro-costing analysis finds that the total direct NHS England provider cost of a non-curative management pathway for higher-risk myelodysplastic syndromes (HR-MDS) reaches £146,921 per patient, with per-patient-per-month costs of £8,721.58 during active azacitidine…
Source →Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Rolles B, et al
In an analysis of 715 higher-risk myelodysplastic syndrome (MDS) patients treated with hypomethylating agents (HMA), baseline IPSS-M disease risk (hazard ratio [HR]: 0.5, p < 0.001) and receipt of allogeneic stem cell transplant (allo-HCT; HR: 0.5, p < 0.001) were the strongest independent predictor…
Source →"Prognostic Significance of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Monocyte-to-Lymphocyte Ratios in Myeloid Neoplasms: A Systematic Review".
Dabir M, et al
A systematic review of 13 studies encompassing 2,847 patients found that elevated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were consistently associated with shorter overall survival in myelodysplastic syndromes (MDS) and acute m…
Source →Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.
Schulz F, et al
A registry-based study of 928 patients from Düsseldorf found that patients reclassified from MDS IB2 to AML under the 2022 ICC criteria behave clinically and biologically differently from true AML with myelodysplasia-related changes (AML-MR), with median overall survival of 19 months for MDS IB2 ver…
Source →The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high-risk myelodysplastic syndromes.
Vrachiolias G, et al
A new study published in the British Journal of Haematology investigates the role of the adenosinergic pathway in mediating resistance to hypomethylating agents — the standard-of-care treatment for high-risk myelodysplastic syndromes (MDS). The research examines how adenosine signalling, a key immun…
Source →